DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Finn RS, Crown JP, Lang I et al.
Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase
(CDK) 4/6 inhibitor, in combination with letrozole vs. letrozole alone for
first-line treatment of ER+/HER2- advanced breast cancer (BC).
Cancer Res 2012;
72 (Suppl. 24) 91s
We do not assume any responsibility for the contents of the web pages of other providers.